Navigation Links
Protein Sciences Responds to Emergent BioSolutions Lawsuit
Date:7/10/2008

that the BLA has been accepted for substantive review by the FDA and PSC is today in the middle of its pre-approval inspection by the FDA and that PSC expects to hear shortly on its proposal for a very significant federal funding. EBS's attempt to destroy and discredit PSC and its senior management team is particularly reprehensible given that PSC's lead product, FluBlok, has the potential to save significant lives and may be a primary weapon in responding to any flu pandemic.

About PSC

PSC is a privately held biotechnology company that uses proprietary recombinant DNA technology to manufacture human and animal vaccines, therapeutics and diagnostics. Our lead product is a human seasonal flu vaccine - FluBlok(R). This product is currently in Phase III clinical trials with the FDA and our BLA for FluBlok has been accepted by the FDA for substantive review on an accelerated basis with an FDA action date of October 18, 2008. FluBlok may have important advantages over the existing flu vaccines and we are well situated to develop a vaccine if an influenza pandemic occurs. Our underlying technology is a viable alternative production platform to the egg-based production methods that currently dominate vaccine production and our 2007 revenues were in excess of $6,000,000, primarily from our GeneXpress and research antigen business.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Enhanced Protein Tomography(TM) Method for Rapid Epitope Determination
2. Large-scale community protein annotation -- WikiProteins
3. The Protein Tomography(TM) Award Now Published on Sidecs Homepage
4. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
5. Sidec Announces the First Protein Tomography(TM) Award at Sidecs Executive Forum at PEGS
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
7. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
8. Marteks lifesDHA(TM) Now Available in Protein-free Powder
9. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
10. Immune system protein starves staph bacteria
11. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Oct. 27 /Xinhua-PRNewswire/ -- Recently, China Green,Material ... Intellectual,Property Office for two patents for Industrialized ... and Industrialized Production,Method of Fully Biodegradable Edible ... applications have both obtained acceptance numbers,200810064592 and ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) today ... study,demonstrating that repeat administration with TRU-015 continues ... rheumatoid arthritis,(RA) signs and symptoms based on ... announced positive results following preliminary,analyses from a ...
... Inc. ("Carna"),announced on October 27, 2008, the signing ... ("SUBC"). Under the terms of this,Agreement, SUBC will ... China., With China,s emergence as a strong ... companies have now established,research and production facilities in ...
Cached Biology Technology:Patent Technologies Keep CGMT in a Leading Position in the Industry 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... MD Researchers from The Johns Hopkins Medical Institutions ... immunohistochemistry to distinguish hydatidiform moles. The related report ... Analytic Validation of a Multiplex Short Tandem Repeat ... The Journal of Molecular Diagnostics . Molar ...
... of sediment cores indicates that biological and chemical changes occurring ... 200,000 years and likely are the result of human-caused climate ... of Colorado at Boulder. While environmental changes at ... be tightly linked with natural causes of climate change -- ...
... 20 Aware, Inc. (Nasdaq: AWRE ), a leading ... results for its third quarter ended September 30, 2009. ... Officer, said, "Earlier today, we announced an agreement to sell ... new fabless semiconductor company being spun out of Infineon. ...
Cached Biology News:Classifying molar pregnancy 2Arctic lake sediments show warming, unique ecological changes in recent decades 2Arctic lake sediments show warming, unique ecological changes in recent decades 3Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Normal sheep serum collected from healthy normal sheep...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Biology Products: